| melanoma
Kimmtrak vs Mektovi
Side-by-side clinical, coverage, and cost comparison for melanoma.Deep comparison between: Kimmtrak vs Mektovi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMektovi has a higher rate of injection site reactions vs Kimmtrak based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mektovi but not Kimmtrak, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kimmtrak
Mektovi
At A Glance
IV infusion
Weekly
gp100/CD3 T cell engager
Oral
Twice daily
MEK inhibitor
Indications
- melanoma
- melanoma
- Non-Small Cell Lung Carcinoma
Dosing
Melanoma 20 mcg IV on Day 1, 30 mcg IV on Day 8, 68 mcg IV on Day 15, then 68 mcg IV once weekly thereafter; administer by intravenous infusion over 15-20 minutes.
melanoma 45 mg orally twice daily in combination with encorafenib; reduce to 30 mg orally twice daily for patients with moderate or severe hepatic impairment.
Non-Small Cell Lung Carcinoma 45 mg orally twice daily in combination with encorafenib.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, vomiting
Serious Cytokine release syndrome, skin reactions, elevated liver enzymes, rashes, pyrexia, hypotension
Most common (>=25%) fatigue, nausea, diarrhea, vomiting, abdominal pain, musculoskeletal pain, visual impairment, constipation, dyspnea, rash, cough
Serious hemorrhage, diarrhea, anemia, dyspnea, pneumonia, arrhythmia, device related infection, edema, myocardial infarction, pleural effusion
Pharmacology
Tebentafusp-tebn is a bispecific gp100 peptide-HLA-A*02:01 directed TCR CD3 T cell engager; it binds to gp100 peptide on HLA-A*02:01-positive uveal melanoma cells and activates polyclonal T cells to release inflammatory cytokines and cytolytic proteins, resulting in direct lysis of uveal melanoma tumor cells.
Binimetinib is a reversible inhibitor of MEK1 and MEK2, upstream regulators of the ERK pathway; combined with encorafenib it targets two different kinases in the RAS/RAF/MEK/ERK pathway for greater anti-proliferative and anti-tumor activity in BRAF mutation-positive tumors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kimmtrak
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Mektovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Kimmtrak
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Mektovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Kimmtrak
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Mektovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Melanoma: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Mektovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KimmtrakView full Kimmtrak profile
MektoviView full Mektovi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.